FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.

Trial Details

NCT ID
NCT07446322
Phase
PHASE2
Sponsor
Oncolytics Biotech
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Bevacizumab
  • FOLFIRI
  • Pelareorep
Locations (sample)
  • Homewood, Alabama, United States|33.47177,-86.80082
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Encino, California, United States|34.15917,-118.50119
  • Koreatown, California, United States|34.05779,-118.30091
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • Histologically confirmed cancer of the colon or rectum with documented metastasis
  • Measurable disease per RECIST v. 1.1
  • Not candidates for curative surgery or curative radiation
  • Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →